No profile data available.
Ernexa Therapeutics Inc. (ERNA) is a healthcare company in the medication development research industry, based in Cambridge, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$14.10 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $3.92 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease.
Ernexa Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $582,000 in fiscal year 2024. In Q1 2026 revenue was $0.
$3.92 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include MindWalk Holdings Corp. (HYFT), Caribou Biosciences, Inc. (CRBU), iBio, Inc. (IBIO), HCW Biologics Inc. (HCWB).